Evaluating diagnostic value of 99mTc-CXCR4 scan in glioblastoma

Phase 1

• Conditions: Glioblastoma.; Malignant neoplasm of brain, unspecified; C71.9

• Registration Number: IRCT20230703058654N1
• Lead Sponsor: Shiraz University of Medical Sciences

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Last Update Posted: 13 November 2023

Recruitment & Eligibility

• Status: Pending
• Sex: All
• Target Recruitment: 15

Inclusion Criteria

The patient has been diagnosed with glioma based on MRI within the last month
The patient is a candidate for surgical resection and has not undergone any type of anti-cancer treatment
The patient's condition is stable for the scan
The patient consents to the scan, and at the time of the scan
Do not be pregnant or breastfeeding

Exclusion Criteria

Patients with multiple masses
Patients who need emergency interventions after initial diagnosis
Patients whose tumor cannot be operated
Patients who do not consent to scan or surgery

Study & Design

• Study Type: interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
The mean amount of radioactivity uptake in low-grade glioma patients. Timepoint: 3 hours after radiopharmaceutical administration. Method of measurement: SPECT/CT imaging.;The mean amount of radioactivity uptake in high-grade glioma patients. Timepoint: 3 hours after radiopharmaceutical administration. Method of measurement: SPECT/CT imaging.;Sensitivity of imaging to detect high-grade glioma. Timepoint: 3 hours after radiopharmaceutical administration. Method of measurement: SPECT/CT imaging and comparison with pathology results.;Sensitivity of imaging to detect low-grade glioma. Timepoint: 3 hours after radiopharmaceutical administration. Method of measurement: SPECT/CT imaging and comparison with pathology results.